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Outcomes of hematopoietic cell transplantation continue to improve. New techniques have reduced trans-
plant toxicities, and there are new sources of hematopoietic stem cells from related and unrelated donors. In
June 2007, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) convened a State of the
Science Symposium (SOSS) in Ann Arbor and identiﬁed 11 high priority clinical trials for the network to
pursue. This article reviews both the status of those trials and the record of achievement of the BMT CTN as it
convenes another SOSS in Grapevine, Texas in February 2014.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION 1. Phase II trial of calcineurin-free regimens in patients
In 2001, the National Heart, Lung, and Blood Institute
(NHLBI) and the National Cancer Institute (NCI) chartered the
Blood and Marrow Transplantation Clinical Trials Network
(BMT CTN) to conduct hematopoietic cell transplantation
(HCT) clinical trials that would advance the standard of care
for transplant patients. Inpreparation for this charter, theﬁrst
State of the Science Symposium (SOSS) was convened that
year. It deﬁned 6 key areas that would frame the scientiﬁc
agenda of the BMT CTN: optimal graft source and composi-
tion, regimen-related toxicity, graft-versus-host disease
(GVHD), infection and immune reconstitution, quality of life/
late effects, and relapse of malignancy after HCT.
In 2007, the BMT CTN had been operational for 6 years,
and it convened a second SOSS in Ann Arbor to frame the
scientiﬁc agenda for the next 7 years. For that SOSS, the
relapse of malignancy area was expanded to 3 committees:
leukemia, lymphoma, and multiple myeloma (MM). Com-
mittees in pediatric diseases, nonmalignant diseases, cell and
gene therapy, and trial design and implementationwere also
added. After the presentation and discussion of all 12 com-
mittees, the committee chairs, together with an international
panel of experts, reviewed the symposium discussions and
ranked the proposed trials. The group reached consensus
regarding 11 questions to which it assigned highest priority.
This article brieﬂy reviews the status of each of those 11
topics and reﬂects on the current challenges and opportu-
nities in BMT clinical research as we approach the third SOSS
to be held at the end of February 2014 in Grapevine, Texas.dgments on page 152.
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Background and Hypothesis. Evolving understanding of
immunologic control mechanisms suggests that manipulation
of cellular populations other than conventional T cells, either
in vivo or ex vivo, may be beneﬁcial. Calcineurin inhibitors
(CNIs) inhibit both regulatory T cells (Treg) and conventional
T cells and may interfere with thymic function [1,2]. It is
possible that observed rates of chronic GVHD relate to the
inability of CNIs to induce long-term tolerance [3-5].
Augmentation of natural or inducible Treg number or func-
tion may mitigate GVHD and facilitate immune competence
while maintaining the graft-versus-leukemia effect [6].
Several approaches to augment Treg numbers or activity are
feasible. Sirolimus-based, CNI-free regimens (eg, sirolimus/
mycophenolate mofetil) may foster Treg while inhibiting
effector T cells. In mouse models, GVHD is prevented, whereas
the graft-versus-leukemia effect is maintained [6]. Extracor-
poreal photopheresis also may enhance Treg numbers while
modulating antigen presenting cell function. These observa-
tions led to the hypothesis that treatment without CNIs would
improve outcomes for high-risk chronic GVHD patients.
Trial Design and Feasibility. The network designed two
parallel phase II studies to lead into a single phase III study,
with all patients receiving sirolimus as initial therapy. The
phase II/III design was a strong recommendation of the
Clinical Trials SOSS Committee. The phase II portion of the
trial was completed in 2013, and the trial continues with a
phase III component that compares sirolimus þ prednisone
to sirolimus þ CNI þ prednisone. This is 1 of only a very few
phase III trials of initial treatment for high-risk chronic GVHD
ever attempted. As of November 2013, patient accrual is onTransplantation.
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complete in early 2016.
2. Phase III comparison of peritransplant stress manage-
ment interventions on quality of life (QOL).
Background and Hypothesis. Many studies have docu-
mented deﬁcits in QOL after HCT, but few have tested in-
terventions to improve QOL and functioning. Data from
single centers suggest that exercise and stress management
improves QOL and functional status in HCT recipients [7-13].
Trial Design and Feasibility. We designed a phase III ran-
domized trial (BMT CTN 0902) to test the hypothesis that an
exercise and stress management program would reduce
fatigue and stress and improve QOL in HCT recipients. We
compared usual care to a stress management intervention
based on exercise and relaxation/imagery techniques in 710
patients. The primary endpoints were QOL and functional
status at day 100 asmeasured by self-assessment. Accrualwas
extremely brisk and was completed within 21/2 years. Final
results will be published later this year. Regardless of results,
the demonstration that such studies can be completed rapidly
in a multicenter setting using the BMT CTN infrastructure will
encourage evaluation of future QOL interventions in HCT.
3. Phase III comparison of tandem autotransplant fol-
lowed by lenalidomide maintenance versus consoli-
dation therapy with bortezomib, lenalidomide, and
dexamethasone followed by lenalinomide mainte-
nance versus immediate maintenance therapy with
lenalidomide in patients receiving a single autotrans-
plant for MM.
Background and Hypothesis.MM is the most common indi-
cation for autologous HCT [14]. The availability of new agents
and combinations now results in complete remission and near
complete remission rates of over 50%, but best long-term sur-
vival is seen in protocols that include autologous trans-
plantation as part of initial therapy [15]. The most appropriate
post-transplant therapy to prolong both progression-free and
overall survival is still undeﬁned.
Trial Design and Feasibility. The Network designed a 3-arm
trial (BMT CTN 0702) to test the hypothesis that there is no
beneﬁt of tandem transplantation in the context of modern
post-transplant therapy for MM. Patients were randomized
to receive 1 of 3 therapies after the ﬁrst transplant: (1) sec-
ond autologous HCT or (2) 4 cycles of combination therapy
with bortezomib, lenalidomide, and dexamethasone or (3)
observation. All patients received lenalidomide maintenance
therapy. This 750-patient trial (250 per arm) completed
accrual ahead of schedule in November 2013. An ancillary
study (PRIMER) will evaluate 7 color ﬂow cytometry to
monitor residual disease by immunophenotype.
4. Phase III comparison of chemotherapy versus unre-
lated donor HCT in patients with high-risk acute
myeloid leukemia (AML) in ﬁrst complete remission.
Background and Hypothesis. AML is the primary indication
for unrelated donor transplantation, although many physi-
cians defer this approach until after chemotherapy failure.
Randomized trials and 2meta-analyses have shown that HLA-
identical sibling grafts improve survival compared with
chemotherapy [16,17]. Survival of AMLpatientswith high-risk
cytogenetics transplanted in ﬁrst remission is similar (45%),whether the donors are HLA-identical siblings or unrelated
volunteers [18]. We will test the hypothesis that unrelated
donor transplantation soon after induction chemotherapy
improves survival of patients with AML compared with
treatment with best chemotherapy.
Trial Design and Feasibility. The committee proposed a
phase III trial comparing unrelated donor HCT to chemo-
therapy for AML patients with high-risk cytogenetics, aged
18 to 60 years. A Southwest Oncology Group (SWOG)-led
collaboration among US cooperative groups recently initi-
ated a trial (S2013) to test the hypothesis that it is possible to
bring at least 60% of high-risk patients to allogeneic HCT in
ﬁrst complete remission with current donor availability.
5. Phase III comparison of full-intensity conditioning
versus reduced-intensity conditioning (RIC) in alloge-
neic HCT recipients with AML aged 30 to 60 years.
Background and Hypothesis. RIC regimens in older patients
with AML in ﬁrst remission are associated with relapse rates
not too dissimilar from those seen with more intensive reg-
imens in younger patients. Thus, the conduct of a prospective
randomized comparison of a conventional intensive pre-
parative regimenwith an RIC regimen in middle-aged (30 to
60 years) patients with AML is warranted.
Trial Design and Feasibility. We designed a randomized,
2-arm,phase III trial (BMTCTN0901) to test thehypothesis that
a reduction in the intensity of conditioning would decrease
treatment-related mortality without increasing relapse, lead-
ing to a safer and equally effective regimen in patients ages 30
to 60 years with AML and myelodysplastic syndrome. Accrual
to this 356-patient trial is ahead of target as of November 2013
and is expected to be complete in the summer of 2015.
6. Phase III comparison of chemotherapy þ dasatinib
versus allogeneic HCT in patients with Phþ acute
lymphocytic leukemia.
Background and Hypothesis. Before the availability of
imatinib and other BCR-ABL tyrosine kinase inhibitors, the
outlook for patients with Phþ acute lymphocytic leukemia
treated with conventional chemotherapy was extremely
poor, and, accordingly, allogeneic HCT was the treatment of
choice. Several groups using imatinib in combination with
conventional chemotherapy reported outcomes in Phþ acute
lymphocytic leukemia that rival those obtained with allo-
geneic HCT [19-21]. Preliminary data suggest that the more
potent tyrosine kinase inhibitor, dasatinib, can be combined
with intensive chemotherapy safely. We will test the hy-
pothesis that modern chemotherapy incorporating a tyro-
sine kinase inhibitor will yield disease-free survival similar to
that achieved with allogeneic HCT.
Trial Design and Feasibility. Because this trial would eval-
uate patients at the time of diagnosis and include those who
would not receive an allogeneic HCT, SWOG led the effort
and followed the suggestion of this committee, designing a
phase III, “biologic assignment” trial (S0805) in which pa-
tients either received an allogeneic HCT in ﬁrst complete
remission if an appropriate donor was available or were
treated with hyper-cyclophosphamide, vincristine, adria-
mycin, dexamethasone (CVAD) and dasatinib. The trial met
its accrual target of 100 patients in September 2013.
7. Phase II trial of reduced-intensity allogeneic HCT in
patients with very high-risk chronic lymphocytic leu-
kemia (CLL).
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tients with CLL have aggressive disease with a shorter overall
survival [22]. Preliminary results with RIC allogeneic HCT in
patients with ﬂudarabine-resistant CLL have yielded
encouraging results [23].
Trial Design and Feasibility. In collaboration with Cancer
and Leukemia Group B (CALGB) (now the Alliance), we
designed a phase II trial to test the hypothesis that RIC allo-
geneic HCT will improve survival in patients with advanced
CLL. The protocol team divided patients into 2 cohorts of 39
(early and advanced). As of November 2013, the advanced
cohort had nearly ﬁnished accrual (35/39), but accrual in the
early disease arm is considerably slower (14/39).
8. Phase II trial of reduced-intensity allogeneic HCT as
primary therapy for peripheral T cell lymphoma.
Background and Hypothesis. Patients with peripheral T cell
lymphomas typically respond to frontline therapy, but most
patients ultimately relapse, leading to shortened survivals
despite the use of autologous HCTas consolidation therapy in
ﬁrst complete remission or as a salvage therapy [24]. These
observations underscore the need for investigation of allo-
geneic HCT in this lymphoma subtype. Progress has been
limited partly because of the low incidence and the hetero-
geneity of histologies in this particular non-Hodgkin lym-
phoma subtype.
Trial Design and Feasibility. The BMT CTN worked closely
with CALGB for 3 years in the design of this trial (CALGB
100901), but the effort was discontinued because of the
rarity of the disease and the low likelihood that the trial
could complete accrual.
9. Phase II trial of reduced-intensity allogeneic HCT in
children with hemophagocytic lymphohistiocytosis
(HLH).
Background and Hypothesis. Hemophagocytic disorders
comprise primarily HLH but include X-linked lymphoproli-
ferative syndrome, Chediak-Higashi syndrome, and Griscelli
syndrome. These nonmalignant syndromes are often fatal
and are characterized by hyperproduction of inﬂammatory
cytokines such as tumor necrosis factor-a. The diagnosis of
HLH can be established by genetic and functional testing.
Allogeneic HCT is the only curative option, but a major bar-
rier to success is 35% treatment-related mortality associated
with intensive conditioning regimens [25].
Trial Design and Feasibility. We designed a multicenter,
phase II trial (BMT CTN 1204) of 35 patients to test the
hypothesis that RIC will result in improved survival by
decreased treatment-related mortality without loss of efﬁ-
cacy for patients with HLH. Pilot data [26,27] suggest that an
RIC regimen is safe and effective in children with nonma-
lignant disorders, including HLH. Accrual began at the end of
2013 and is expected to last 3 years.
10. Phase II trial of autologous HCT for refractory Crohn’s
disease.
Background and Hypothesis. Preliminary data suggest that
Crohn’s disease may also be amenable to therapy with
autologous HCT, which has shown promise in controlling
several autoimmune diseases [28-30]. The mechanism of
disease control is purported to be through resetting of the
patient’s immune system. Currently, 3 national trials aresupported by the National Institute of Allergy and Infectious
Diseases of autologous HCT for autoimmune diseases. Un-
controlled single-center data suggest efﬁcacy for autologous
HCT in severe Crohn’s disease [31,32]. A multinational trial is
currently accruing patients in Europe.
Trial Design and Feasibility. We proposed to test the hy-
pothesis that autologous HCT with positively selected CD34þ
peripheral blood progenitor cells would result in improved
survival for patients with severe Crohn’s disease in a multi-
center phase II trial. The feasibility of this trial was ques-
tioned almost immediately because HCTs occur only rarely
for this and other autoimmune diseases in the United States,
in large part because of the difﬁculty in obtaining insurance
coverage for the clinical costs of these procedures. The trial
was never initiated.
11. Cell therapy: phase II trial of HLA-matched, viral-
speciﬁc cytotoxic T lymphohocytes to treat adenoviral
infections.
Background and Hypothesis. Although multivirus-speciﬁc
cytotoxic T lymphohocytes have proven efﬁcacy, the current
methodology using repeated stimulation with antigen pre-
senting cells expressing viral antigens is too cumbersome to
use in multicenter trials [33]. Similar approaches using allo-
depleted T cells are still being optimized [34,35]. Alternative
means of reconstituting antiviral immunity include rapid
selection processes using tetramer selection or g-interferon
capture, but the former restricts speciﬁcity,whereas the latter
produces low yields. Another option is banked allogeneic
lines, which could be manufactured with the assistance of
the Production Assistance for Cellular Therapies program; a
study used allogeneic Epstein-Barr virusespeciﬁc cytotoxic
T lymphohocytes lines in patients with post-transplant
lymphoma [36].
Trial Design and Feasibility. Using protocol templates and
case report forms from the BMT CTN, the Production Assis-
tance for Cellular Therapies program led a phase II multi-
center study of banked allogeneic trivirus-speciﬁc T cells for
50 allogeneic HCT recipients with resistant cytomegalovirus,
adenoviral, or Epstein-Barr virus infection (NCT00711035).
The trial was sponsored by the NHLBI, accrual was completed
in 2011, and its results were published last year. Sponsored
by NHLBI, and completed accrual in 2011. Its results were
published last year [37].
The last SOSS also unanimously recommended that the
BMT CTN form a Biomarkers Committee that would consider
appropriate standardization of sample banks and potential
processing across all network protocols. The search for bio-
markers is proceeding in many other diseases, and the BMT
CTN would beneﬁt from discussion and interchange with
those groups on a regular basis. Not only did the network
form such a committee, which now reviews the biospecimen
collection in all new protocols, the committee designed an
additional trial to establish a cohort of prospectively
collected biologic samples from 1500 patients (BMT CTN
1202) to be a shared resource for future allogeneic HCT trials.
Accrual is extremely brisk and well ahead of projections,
with completion estimated in 21/2 years.
Thus, 9 of the 11 trials recommended were launched; 4
have already completed patient accrual, and 5 are ongoing.
Two were never launched because a more careful analysis
determined they were infeasible. During this time, the
Network also completed 9 protocols recommended by the
initial SOSS in 2001 and continued or launched an additional
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lishing 26 peer-reviewed papers with several more currently
under review. This remarkable record of achievement, which
includes the accrual of almost 4000 patients to 25 clinical
trials in the past 6 years, is due to several important factors.
Perhaps the most important is the NIH collaboration that
enabled the establishment of the BMT CTN: both NHLBI and
NCI have jointly supported the BMT CTN from its initiation.
The issues addressed by the BMT CTN include priority areas
for both Institutes, and the network’s ability to successfully
address them has been greatly enhanced by inter-Institute
cooperation and resource-sharing, including emendation of
NIH policies and procedures to accelerate the design and
implementation of important trials. This culture of collabo-
ration extends to other Networks and protocol team mem-
bers who frequently face shifting priorities, lack of access to
new drugs, and elusive clinical equipoise in their search for
the common ground needed for successful protocols.
A second instrumental factor is the strong and steady
leadership of the BMT CTN Steering Committee, with its
constant efforts to harmonize efforts within the Network as
well as its commitment to work effectively with the NCI
cooperative groups and other networks and consortia. A third
key factor was the transparency, inclusiveness, and external
validation of the 2007 SOSS process itself. To gain the widest
perspectives possible, individual members of the BMT CTN
Steering Committee each participated in only 1 SOSS com-
mittee and all committees were composed primarily of
individuals outside the Network leadership. Additionally,
members of the NCI cooperative groups were included in all
the malignancy committees (leukemia, lymphoma, MM) and
several other committees. A panel of external international
experts evaluated all the recommendations and led vigorous
questionperiods after each committee presentation. All these
factors led to a remarkable consensus at the end of the con-
ference. The 2007 symposium has served as the template for
the upcomingmeeting inTexas,whichweexpect to represent
another key milestone in our common efforts to make HCT
safer, more effective, and more available to all patients who
might beneﬁt from this important therapy.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to disclose.
REFERENCES
1. Beschorner WE, Suresch DL, Shinozawa T, et al. Thymic immunopa-
thology after cyclosporine: effect of irradiation and age on medullary
involution and recovery. Transplant Proc. 1988;20:1072-1078.
2. Shinozawa T, Beschorner WE, Hess AD. The thymus and prolonged
administration of cyclosporine. Transplant. 1990;50:106-111.
3. Kansu E, Gooley T, Flowers ME, et al. Administration of cyclosporine for
24 months compared with 6 months for prevention of chronic graft-
versus-host disease: a prospective randomized clinical trial. Blood.
2001;98:3868-3870.
4. Beschorner WE, Hess AD, Shinn CA, et al. Transfer of cyclosporine-
associated syngeneic graft-versus-host disease by thymocytes. Resem-
blance to chronic graft-versus-host disease. Transplantation. 1988;45:
209-215.
5. Santos GW, Hess AD, Vogelsang GB. Graft-versus-host reactions and
disease. Immunol Rev. 1985;88:169-192.
6. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory
T-cell trafﬁcking and survival predict effective strategies to control
graft-versus-host disease following allogeneic transplantation. Blood.
2007;109:2649-2656.
7. Syrjala KL, Donaldson GW, Davis MW, et al. Relaxation and imagery
and cognitive-behavioral training reduce pain during cancer treat-
ment: a controlled clinical trial. Pain. 1995;63:189-198.8. Dimeo F, Bertz H, Finke J, et al. An aerobic exercise program for patients
with haematological malignancies after bone marrow transplantation.
Bone Marrow Transplant. 1996;18:1157-1160.
9. Dimeo F, Fetscher S, Lange W, et al. Effects of aerobic exercise on the
physical performance and incidence of treatment-related complica-
tions after high-dose chemotherapy. Blood. 1997;90:3390-3394.
10. Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al. Effects of physical
activity on the fatigue and psychologic status of cancer patients during
chemotherapy. Cancer. 1999;85:2273-2277.
11. Hayes S, Davies PS, Parker T, et al. Quality of life changes following
peripheral blood stem cell transplantation and participation in amixed-
type, moderate-intensity, exercise program. Bone Marrow Transplant.
2004;33:553-558.
12. Wilson RW, Jacobsen PB, Fields KK. Pilot study of a home-based aerobic
exercise program for sedentary cancer survivors treated with hematopoi-
etic stem cell transplantation. Bone Marrow Transplant. 2005;35:721-727.
13. Carlson LE, Smith D, Russell J, et al. Individualized exercise program for
the treatment of severe fatigue in patients after allogeneic hemato-
poietic stem-cell transplant: a pilot study. Bone Marrow Transplant.
2006;37:945-954.
14. Pasquini MC. CIBMTR Summary Slides Part 1. 2005;Slides Part 1.
15. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly
diagnosed multiple myeloma based on Mayo Stratiﬁcation of Myeloma
and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin
Proc. 2007;82:323-341.
16. Yanada M, Matsuo K, Emi N, et al. Efﬁcacy of allogeneic hematopoietic
stem cell transplantation depends on cytogenetic risk for acute
myeloid leukemia in ﬁrst disease remission: a metaanalysis. Cancer.
2005;103:1652-1658.
17. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/
SAKK donor versus no-donor analysis of myeloablative HLA-identical
sibling stem cell transplantation in ﬁrst remission acute myeloid leu-
kemia in young and middle-aged adults: beneﬁts for whom? Blood.
2007;109:3658-3666.
18. Tallman MS, Dewald GW, Gandham S, et al. Impact of cytogenetics on
outcome of matched unrelated donor hematopoietic stem cell trans-
plantation for acute myeloid leukemia in ﬁrst or second complete
remission. Blood. 2007;110:409-417.
19. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and
promising outcome by combination of imatinib and chemotherapy for
newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a
phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol.
2006;24:460-466.
20. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia
chromosome-positive acute lymphocytic leukemia with hyper-CVAD
and imatinib mesylate. Blood. 2004;103:4396-4407.
21. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined
with induction or consolidation chemotherapy in patients with de
novo Philadelphia chromosome-positive acute lymphoblastic leuke-
mia: results of the GRAAPH-2003 study. Blood. 2007;109:1408-1413.
22. Montserrat E. New prognostic markers in CLL. Hematol Am Soc Hematol
Educ Progr. 2006;279-284.
23. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell trans-
plantation after nonmyeloablative conditioning for advanced chronic
lymphocytic leukemia. J Clin Oncol. 2005;23:3819-3829.
24. Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma.
Blood. 2006;107:1255-1264.
25. Filipovich AH. Hemophagocytic lymphohistiocytosis and related dis-
orders. Curr Opin Allergy Clin Immunol. 2006;6:410-415.
26. Cooper N, Rao K, Gilmour K, et al. Stem cell transplantation with
reduced-intensity conditioning for hemophagocytic lymphohistiocy-
tosis. Blood. 2006;107:1233-1236.
27. Baker KS, Eapen M, Gross T, et al. Unrelated donor hematopoietic cell
transplant (HCT) for hemophagocytic lymphohistiocytosis (HLH).
Blood. 2006;108:174.
28. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosup-
pressive therapy and autologous peripheral blood stem cell trans-
plantation for severe multiple sclerosis. Blood. 2003;102:2364-2372.
29. Hough RE, Snowden JA, Wulffraat NM. Haemopoietic stem cell trans-
plantation inautoimmunediseases: aEuropeanperspective.Br JHaematol.
2005;128:432-459.
30. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosup-
pressive therapy and autologous hematopoietic cell transplantation for
severe systemic sclerosis: long-term follow-up of the US multicenter
pilot study. Blood. 2007;110:1388-1396.
31. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem
cell transplantation in patients with refractory Crohn’s disease.
Gastroenterology. 2005;128:552-563.
32. Leung Y, Geddes M, Storek J, et al. Hematopoietic cell transplantation for
Crohn’s disease: is it time? World J Gastroenterol. 2006;12:6665-6673.
33. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes
speciﬁc for multiple viruses expand and produce clinically relevant
effects in immunocompromised individuals. Nat Med. 2006;12:
1160-1166.
J.L.M. Ferrara / Biol Blood Marrow Transplant 20 (2014) 149e153 15334. Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immuno-
therapy with allodepleted donor T-cells improves immune reconsti-
tution after haploidentical stem cell transplantation. Blood. 2006;108:
1797-1808.
35. Solomon SR, Mielke S, Savani BN, et al. Selective depletion of allor-
eactive donor lymphocytes: a novel method to reduce the severity of
graft-versus-host disease in older patients undergoing matched sibling
donor stem cell transplantation. Blood. 2005;106:1123-1129.36. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell
therapy for EBV-positive posttransplantation lymphoproliferative dis-
ease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:
1123-1131.
37. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of
banked third-party virus-speciﬁc T cells to treat severe viral infections
after hematopoietic stem cell transplantation. Blood. 2013;121:
5113-5123.
